| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5891375 | Bone | 2013 | 12 Pages |
Abstract
⺠Endosteal new bone formation is not disrupted in the Avy/a mouse model for type 2 diabetes mellitus. ⺠Rosiglitazone inhibits endosteal new bone formation to the same extent in diabetic and nondiabetic animals. ⺠Rosiglitazone alters the bone marrow constituents by significantly increasing the number of adipocytes at the site of distraction osteogenesis. ⺠Rosiglitazone treatment disrupts the well-organized microstructure of cell/matrix during osteogenesis normally exhibited in this model. ⺠Endosteal new bone formation may be affected in human patients on anti-diabetic therapy with rosiglitazone.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Developmental Biology
Authors
Lichu Liu, James Aronson, Beata Lecka-Czernik,